Clinical trial ZEST
A Randomized Phase 3 Double-Blinded Study Comparing Efficacy of Niraparib to Placebo in Participants with Either HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Based on Presence of Circulating Tumor DNA after Definitive Therapy
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | GSK |
| EudraCT Identifier | 2020-003973-23 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04915755 |
| Last update |